Table 1.
Baseline clinical characteristics of degenerative parkinsonism and control groups
| PD | MSA-P | PSP | CBS | Control | Pval | Pval | |
|---|---|---|---|---|---|---|---|
| # | 280 | 21 | 41 | 28 | 208 | Degenerative PS and Control | Degenerative PS |
| Age (years) | 69.8 ± 10.8 (42–92) | 69.0 ± 11.0 (43–86) | 72.7 ± 7.6 (44–85) | 73.6 ± 7.8 (56–85) | 69.9 ± 10.6 (42–91) | 0.25a | 0.14a |
| Disease duration (years) | 1.3 ± 0.8 (0–3) | 1.5 ± 0.8 (0.5–3) | 1.6 ± 0.9 (0.3–3) | 1.6 ± 0.7 (0.5–3) | NA | 0.09a | |
| Male/female ratio | 1.12 (148/132) | 1.1 (11/10) | 1.05 (21/20) | 1.15 (15/13) | 0.66 (83/125) | 0.07b | 0.99b |
| S uptake | 1.79 ± 0.64 (0.24–4.14) | 1.35 ± 0.56 (0.49–3.17) | 1.38 ± 0.60 (0.39–2.82) | 1.96 ± 0.76 (0.20–4.04) | 3.16 ± 0.55 (1.78–5.33) | All < 0.005a | |
| C uptake | 2.25 ± 0.71 (0.31–4.63) | 1.80 ± 0.61 (0.80–3.56) | 1.70 ± 0.64 (0.48–3.17) | 2.20 ± 0.84 (0.25–4.24) | 3.37 ± 0.62 (1.55–6.05) | ||
| P uptake | 1.44 ± 0.64 (0.19–3.76) | 1.01 ± 0.54 (0.14–2.88) | 1.13 ± 0.60 (0.17–2.59) | 1.78 ± 0.75 (0.17–3.89) | 3.01 ± 0.54 (1.44–4.79) | ||
| C/P ratio (most affected side) | 1.86 ± 0.67 (0.47–6.73) | 2.35 ± 1.37 (1.26–6.79) | 1.72 ± 0.46 (0.79–2.82) | 1.37 ± 0.41 (0.72–2.65) | 1.13 ± 0.15 (0.71–1.75) | ||
| Striatal AI | 19.8 ± 14.8 (0.4–73.4) | 19.7 ± 18.0 (0.4–63.2) | 13.7 ± 10.9 (0.1–44.5) | 31.3 ± 29.4 (1.6–150.6) | 4.8 ± 3.7 (0.0–19.2) | ||
Mean (left + right) VOIs uptake, C/P ratio and striatal AI are also shown. Results are expressed Mean ± SD (range)
Statistical analysis: aKruskall Wallis test, bChi-squared test